Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serological evidence of sarbecovirus exposure along Sunda pangolin trafficking pathways.
Worthington BM, Wong PY, Kumaree KK, Prigge TL, Ng KH, Liao Y, Martelli P, Churgin S, Lee FK, Perkins C, Bradley M, Pierce MP, Shum MH, Miot EF, Cheung WY, McIlroy SE, Nash HC, Wirdateti, Semiadi G, Tan CW, Wang LF, Ades G, Baker DM, Dingle C, Pybus OG, Holmes EC, Leung GM, Guan Y, Zhu H, Bonebrake TC, Lam TTY. Worthington BM, et al. Among authors: tan cw. BMC Biol. 2024 Nov 26;22(1):274. doi: 10.1186/s12915-024-02074-x. BMC Biol. 2024. PMID: 39593133 Free PMC article.
Humoral Immunity Profiling to Pandemic and Bat-Derived Coronavirus Variants: A Geographical Comparison.
Fathi P, Alfonso AL, Yek C, Putman Z, Drew M, Esposito D, Zaidi I, Chea S, Ly S, Sath R, Lon C, Chea H, Leang R, Huy R, Ly S, Seng H, Tan CW, Zhu F, Wang LF, Oliveira F, Sadtler K, Manning J. Fathi P, et al. Among authors: tan cw. Adv Sci (Weinh). 2024 Oct 29:e2403503. doi: 10.1002/advs.202403503. Online ahead of print. Adv Sci (Weinh). 2024. PMID: 39471070
Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster.
Tang YS, Tan CW, Chong KC, Chen C, Sun Y, Yiu K, Ling KC, Chan KKP, Peiris M, Mok CKP, Hui DS. Tang YS, et al. Among authors: tan cw. Int J Infect Dis. 2024 Oct 18;149:107271. doi: 10.1016/j.ijid.2024.107271. Online ahead of print. Int J Infect Dis. 2024. PMID: 39426493 Free article.
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
Cuker A, Kavakli K, Frenzel L, Wang JD, Astermark J, Cerqueira MH, Iorio A, Katsarou-Fasouli O, Klamroth R, Shapiro AD, Hermans C, Ishiguro A, Leavitt AD, Oldenburg JB, Ozelo MC, Teitel J, Biondo F, Fang A, Fuiman J, McKay J, Sun P, Rasko JEJ, Rupon J; BENEGENE-2 Trial Investigators. Cuker A, et al. N Engl J Med. 2024 Sep 26;391(12):1108-1118. doi: 10.1056/NEJMoa2302982. N Engl J Med. 2024. PMID: 39321362 Clinical Trial.
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Poh XY, Torres-Ruesta A, Yoong T, Wong N, Tan CW, Rouers A, Chavatte JM, Goh YS, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Neo V, Kam IKJ, Huang Y, Hor PX, Loh CY; PRIBIVAC study group; Yeoh AY, Lim DRX, Chia W, Ren EC, Lin RTP, Fong SW, Renia L, Lye DC, Wang LF, Ng LFP, Young BE. Poh XY, et al. Among authors: tan cw. Vaccine. 2024 Nov 14;42(25):126275. doi: 10.1016/j.vaccine.2024.126275. Epub 2024 Sep 5. Vaccine. 2024. PMID: 39241318 Free article. Clinical Trial.
424 results